您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > 2,3-Butanedione-2-monoxime
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
2,3-Butanedione-2-monoxime
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
2,3-Butanedione-2-monoxime图片
CAS NO:57-71-6
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
100g电议

产品介绍
2,3-Butanedione-2-monoxime (Diacetyl monoxime) 是一种肌球蛋白 ATPase 抑制剂,是一种骨骼肌和心肌收缩抑制剂。
Cas No.57-71-6
别名2,3-丁烷二酮一肟,BDM|Diacetyl Monoxime|NSC 660|NSC 116103
化学名2,3-butanedione, 2-oxime
Canonical SMILESCC(/C(C)=N/O)=O
分子式C4H7NO2
分子量101.1
溶解度DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 30 mg/ml,PBS (pH 7.2): 2 mg/ml
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

2,3-Butanedione-2-monoxime is a myosin ATPase inhibitor.

Myosin, an ATPase, can convert chemical energy into directed movement and is regarded as a molecular motor. Myosin has various shapes and sizes. More than 11 myosin classes have been identified, and more will be found. The common feature of all of these molecules is a section close to the N terminus, which can be identified as a motor domain.

In vitro: 2,3-Butanedione-2-monoxime (BDM), a general probe of myosin function, was widely used in muscle research as a low-affinity but specific chemical phosphatase that could reversibly inhibit the myosin cross-bridge cycle. It was found that wild-type cells treated with BDM at 20 mM for around two generation times were smaller than untreated controls and showed a septation index about twice that observed in the absence of the inhibitor. Moreover, the organization of actin at the cell poles was disorganized in the presence of BDM, however, cells formed a cytokinetic actin ring. In addition, when nitrogen-starved stationary-phase cells were reinoculated into fresh medium in the presence of BDM, the time taken to repolarize the actin cytoskeleton and to resume the characteristic vegetative cell shape were both delayed substantially [1].

In vivo: So far, there is no animal in vivo data reported.

Clinical trial: So far, no clinical study has been conducted.

Reference:
[1] May KM, Wheatley SP, Amin V, Hyams JS.  The myosin ATPase inhibitor 2,3-butanedione-2-monoxime (BDM) inhibits tip growth and cytokinesis in the fission yeast, Schizosaccharomyces pombe. Cell Motil Cytoskeleton. 1998;41(2):117-25.